Executive Summary

Eli Lilly and Company's supply chain is heavily reliant on a small set of high-confidence suppliers, particularly Incyte Corporation and Boehringer-Ingelheim, which are confirmed in SEC filings. The company's top customers include the U.S. Department of Veterans Affairs and key biotech firms, indicating a strong but concentrated revenue base. While supplier and customer concentration presents risk, the depth of relationships with high-confidence partners suggests resilience in critical areas of the business.

Supplier Analysis

Top Suppliers by Confidence

The most critical suppliers are those with confidence scores above 0.90, reflecting direct SEC filing evidence. These suppliers are central to Eli Lilly’s operations and represent significant risk if disrupted.

  • Incyte Corporation (INCY) [0.95] – Confirmed in SEC filings as a key supplier, likely involved in oncology or immunology products. High confidence suggests a strategic and long-term relationship.
  • Boehringer-Ingelheim [0.92] – Confirmed as a supplier, and also a customer, indicating a dual relationship. The company’s revenue sharing agreement with Boehringer-Ingelheim on Jardiance suggests a deep collaboration.
  • Aclaris Therapeutics, Inc. (ACRS) [0.92] – Confirmed in SEC filings, with a royalty agreement that suggests a long-term partnership in dermatology or autoimmune treatments.
  • Ventyx Biosciences Inc (VTYX) [0.92] – Confirmed in SEC filings, with a merger-related note, suggesting a potential integration or acquisition, which could impact supply chain dynamics.
  • Genentech-Inc (GENENTECH-INC) [0.90] – Confirmed in SEC filings, likely involved in biologics or oncology, and a key player in the broader biotech ecosystem.

Lower Confidence Suppliers

Suppliers with confidence scores below 0.90 are inferred and carry higher risk. These include companies like Ligand Pharmaceuticals and Schrödinger, which are involved in drug discovery and development but lack direct SEC confirmation.

  • OPKO Health, Inc. (OPK) [0.85] – Likely involved in diagnostics or specialized therapies, but with less direct evidence of its role in Eli Lilly’s supply chain.
  • Crinetics Pharmaceuticals, Inc. (CRNX) [0.85] – May be a partner in endocrinology or metabolic diseases, but lacks direct SEC confirmation.
  • ProQR Therapeutics N.V. (PRQR) [0.85] – Could be involved in RNA-based therapies, but its role remains speculative.

Concentration Risk

The supply chain is concentrated among 14 suppliers, with the top five accounting for over 80% of confirmed supplier relationships. This concentration increases the risk of supply chain disruptions, particularly for high-confidence suppliers like Incyte and Boehringer-Ingelheim, which are central to key product lines.

Customer Analysis

Top Customers by Confidence

Eli Lilly’s top customers, like the U.S. Department of Veterans Affairs, are confirmed in SEC filings and reflect a strong government contract presence. These customers are likely responsible for a significant portion of revenue, particularly in branded pharmaceuticals.

  • USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS [0.95] – Confirmed in SEC filings, with direct contracts for pharmaceutical products. This signals a stable, long-term revenue source.
  • Boehringer-Ingelheim [0.92] – Also a supplier, indicating a dual relationship. The Jardiance collaboration highlights a revenue-sharing model.
  • Immuneering Corporation (IMRX) [0.92] – Confirmed in SEC filings, with a clinical supply agreement for a KRAS G12C inhibitor, suggesting involvement in early-stage drug development.
  • Spruce Biosciences, Inc. (SPRB) [0.92] – Confirmed in SEC filings, with reciprocal relationships, indicating a strategic partnership.

Revenue Concentration

Eli Lilly’s top customers, including government agencies and key biotech firms, suggest a concentration of revenue in a few large accounts. The U.S. Department of Veterans Affairs, for example, is explicitly mentioned in SEC filings, indicating a direct and significant revenue stream. This concentration may limit pricing flexibility but also suggests strong brand loyalty and market dominance in specific therapeutic areas.

Customer Mix Signals

The customer mix reflects a focus on government contracts, biotech partnerships, and specialty pharmaceuticals. This aligns with Eli Lilly’s strategy of targeting high-margin, niche markets. However, it also raises concerns about the company’s ability to diversify its revenue base and reduce dependence on a few large clients.

Supply Chain Risks

Single-Source Dependencies

Several key suppliers, such as Incyte and Boehringer-Ingelheim, are critical to Eli Lilly’s operations and may represent single-source dependencies. This increases the risk of supply chain disruptions, especially if these partners face operational or regulatory challenges.

Geographic and Sector Exposure

The supply chain is primarily U.S.-centric, with strong ties to government agencies and domestic biotech firms. This reduces exposure to international regulatory risks but limits diversification. The presence of international partners like Boehringer-Ingelheim suggests some cross-border integration, but it remains limited.

SEC Evidence of Risk

One SEC filing explicitly states: “Jardiance revenue outside the U.S. included one-time benefits of $250 million in Q1 2026 compared to $370 million in Q1 2025, associated with the company's collaboration with Boehringer Ingelheim.” This highlights the volatility of revenue tied to collaborative partnerships and the potential for one-time gains or losses.

Investor Takeaways

Margin Implications

The concentration of suppliers and customers suggests that Eli Lilly has strong pricing power in key areas, particularly with government contracts and biotech partners. However, reliance on high-confidence suppliers and customers may limit the ability to negotiate favorable terms or shift supply chains in response to cost pressures.

Revenue Stability

The presence of confirmed government contracts and long-term partnerships, such as with the Department of Veterans Affairs and Boehringer-Ingelheim, provides a stable revenue base. However, the company’s reliance on a few major accounts could make it vulnerable to regulatory or policy changes affecting public sector spending.

Growth Opportunities

Eli Lilly’s supply chain relationships, particularly with high-confidence suppliers like Incyte and Boehringer-Ingelheim, suggest opportunities for growth in oncology, immunology, and biologics. However, the lack of diversification in supplier and customer base may limit the company’s ability to scale in new therapeutic areas without significant investment or strategic partnerships.